Lupin Limited · NSE:LUPIN
Lupin — Q3 FY2019 Earnings Presentation
16 slides from Lupin's earnings presentation, Feb 6, 2019
Slide 1: Lupin Limited Investor Presentation Q3 FY2019
LUPIN LIMITED Investor presentation Q3 FY 2019 Feb 06, 2019
Slide 2: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diffe
Slide 3: Lupin – Awards and Accolades
Lupin – Awards and Accolades • Walmart Supplier of the Year Award - 2018 • Dr. Desh Bandhu Gupta inducted into the ‘Hall of Fame’, CNBC-TV18 – India Business Leader Awards 2018 • Vinita Gupta: Vogue and IBM Businesswoman of the year - 2018 • Vinita Gupta selected Women of Worth by Outlook Business -
Slide 4: Q3FY19 Snapshot
Q3FY19 Snapshot Sales (INR mn, YoY growth) Important developments India, Regulatory 11,902 , 11% North America, 14,174 , (1%) Mr. Nilesh.D.Gupta • WL update - Pithampur (Unit 2) re-inspected Managing Director Lupin Limited • Mandideep and Pithampur (Unit 3) facilities also Total inspected by the USF
Slide 5: Tracking FY19 priorities: 9MFY19 scorecard
Tracking FY19 priorities: 9MFY19 scorecard Generics US business getting back on growth mode - Average market share for our products - 32.3%1 (for Dec qtr.) India - Continue to outpace industry growth and gain market share; growing ~1.3x faster than IPM within the chronic segment 2 Cost control
Slide 6: Our Strategic Vision: Well-Diversified Pharma business
Our Strategic Vision: Well-Diversified Pharma business Strong Complex Specialty Focus Foundation Generics Focus Amongst the Top 10 Investing heavily in Committed to building a generic companies in the developing high barrier strong specialty business World products Sustain and Grow Evolve portfolio
Slide 7: Q3FY19 Financial Results Review
Q3FY19 Financial Results Review
Slide 8: P&L Highlights – Q3 FY19
P&L Highlights – Q3 FY19 QoQ YoY Amount in INR mn Q3 FY19 % of sales Q2 FY19 % of sales Q3 FY18 % of sales growth growth Net sales 43,779[1] 100.0% 38,909 100.0% 12.5% 39,004 100.0% 12.2% Other operating income 1,269 601 753 Total revenue 45,048 39,510 14.0% 39,757 13.3% Gross profit 27,770 63.4% 24
Slide 9: P&L Highlights – 9M FY19
P&L Highlights – 9M FY19 Amount in INR mn 9M FY19 % of sales 9M FY18 % of sales YoY growth Net sales 120,434[1] 100.0% 115,814 100.0% 4.0% Other operating income 2,684 2,156 Total revenue 123,118 117,970 4.4% Gross profit 76,055 63.2% 76,696 66.2% (0.9%) (excl. other operating income) EBITDA 22,875
Slide 10: North America
Q3FY19 North America 32% YoY QoQ 1.0% 13.5% US revenues getting back on growth mode Lupin consolidating its position in US1 US quarterly sales ($ mn) 213 224 194 168 171 Q3 FY18 Q4 FY18 Q1 FY19 Q2 FY19 Q3 FY19 US portfolio progressing • US business is getting back on growth mode; planned launch of L
Slide 11: India
Q3FY19 India 27% YoY QoQ 11.4% 1.1% Healthy YoY growth Continue to outpace industry growth India quarterly Sales (INR bn) Q3 FY19 Growth1 Lupin Rank1 MAT MAT 11.9 12.0 11.9 Therapy Market Lupin 10.7 Dec-14 Dec-18 9.6 Acute 9 5 14 12 Chronic 13 17 5 4 Cardiac 13 15 2 3 Anti-diabetics 16 23 5 3 Q3 FY1
Slide 12: APAC
Q3FY19 APAC 16% YoY 2.9% QoQ 11.9% APAC sales evolution (INR bn) 1.2 1.6 1.2 Performance highlights 1.1 1.1 Japan 5.6 5.1 5.0 5.1 5.7 • Growth driven on strong volume uptick in baseline products, offsetting impact of biennial price cut Q3 FY18 Q4 FY18 Q1 FY19 Q2 FY19 Q3 FY19 • bEtanercept filing pro
Slide 13: Developed and Emerging Markets
Other markets • Germany: EUR 6.9 mn sales in Q3FY19 Developed • ARV’s, Women´s Health and CNS are the key focus therapeutic segments EU5 • NaMusclaTM - Launched with Orphan drug designation in UK and Germany; Partnering discussions ongoing for commercialization in other EU territories • 4th largest
Slide 14: Manufacturing and R&D – Diverse Global Network
Manufacturing and R&D – Diverse Global Network Global Commercial Presence OPERATIONS 100 25 9 Countries where Countries with Countries with RESEARCH products are sold marketing offices subsidiaries 18 9 Manufacturing Sites R&D Sites • 8 USFDA approved sites • 412 US ANDAs; 258 approved • 12 USFDA in
Slide 15: Continued investments in growth initiatives
Continued investments in growth initiatives Invested INR 4.3 bn or 9.7% of sales on R&D in Q3FY19 at 9 R&D sites globally Optimizing R&D spend US Pipeline R&D Spend (INR Bn) % of sales 5.0 12.2% 14.0% 412 cumulative filings 4.5 9.7% 10.1% 9.9% 12.0% 4.0 9.7% 3.5 10.0% 3.0 8.0% 2.5 4.8 154 pending ap
Slide 16: Thank You!
SC in LUPIN THANK YOU! :